Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market
Emerging technologies in peripheral nerve stimulation are expected to play a pivotal role in opening up new markets and driving growth in the neuromodulation device market in the years ahead. As a result, the pipeline is rich with products designed to address a growing number of patients with long-term pain and other chronic conditions, many of whom have no other treatment options.
You may also be interested in...
In the market for neuromodulation devices, the largest opportunity is in the treatment of chronic pain, a condition that affects more than 1.5 billion people worldwide. Innovation is driving growth in this sector as companies develop next-generation neuromodulation technologies designed to improve outcomes, and resolve some of the problems with existing devices; these technologies will significantly expand the treatable population, and will allow companies both large and small to capture market share based on device efficacy and the strength of clinical evidence.
Neuromodulation start-up Helius Medical Technologies is employing a simpler, more primal connection to send potentially therapeutic signals to the brain – the tongue. The company is entering pivotal clinical trials to test the technology in select patients with traumatic balance disorder and traumatic brain injury, and evaluating the device for use in patients with multiple sclerosis.
Data from two trials of vagus nerve stimulation to treat heart failure, sponsored by Boston Scientific and Cyberonics, respectively, were not particularly positive for the future of this therapy. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.